AstraZeneca Announced Sunday, Phase 3 CLARITY-Gastric01 Trial Met Primary Overall Survival Endpoint; Sone-Ve Reduced Risk Of Death By 53% In Later-Line CLDN18.2-Positive Advanced Gastric Cancer

Loading news article.

AstraZeneca Announced Sunday, Phase 3 CLARITY-Gastric01 Trial Met Primary Overall Survival Endpoint; Sone-Ve Reduced Risk Of Death By 53% In Later-Line CLDN18.2-Positive Advanced Gastric Cancer | WAPE

AstraZeneca Announced Sunday, Phase 3 CLARITY-Gastric01 Trial Met Primary Overall Survival Endpoint; Sone-Ve Reduced Risk Of Death By 53% In Later-Line CLDN18.2-Positive Advanced Gastric Cancer

Article summary

Related companies

Comments —